

# NeoDynamics publishes prospectus in connection with forthcoming rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.

The Board of Directors of NeoDynamics AB (publ) ("NeoDynamics" or the "Company") has prepared a prospectus (the "Prospectus") relating to the rights issue of shares of approximately SEK 69 million (the "Rights Issue"), which was resolved by the Extraordinary General Meeting held on February 25, 2022. The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.

## Summary of the Rights Issue

- One (1) existing share in the Company entitles to one (1) subscription right. One (1) subscription right entitles the holder to subscribe for one (1) new share, i.e., a subscription ratio of 1:1.
- The subscription price is set at SEK 1.15 per new share, which, assuming that the Rights Issue is fully subscribed, results in the Company receiving approximately SEK 69.3 million before deductions for issue costs.
- Certain existing shareholders have expressed their support for the Rights Issue through subscription commitments amounting to approximately SEK 27.8 million, corresponding to approximately 40 percent of the Rights Issue. Furthermore, the Company has entered into agreements on issue guarantees of approximately SEK 41.5 million, corresponding to approximately 60 percent of the Rights Issue, which secures the Rights Issue to 100 percent.

For complete information on the Rights Issue, please see the published Prospectus.

## Prospectus

The Prospectus has been prepared in connection with the forthcoming Rights Issue and has today, on March 4, 2022, been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, which contains complete terms and conditions, is available on the Company's, Nordic Issuing AB's and Redeye AB's respective websites ([www.neodynamics.com](http://www.neodynamics.com), [www.nordic-issuing.se](http://www.nordic-issuing.se) and [www.redeye.se](http://www.redeye.se)). The Prospectus will also be available on the Swedish Financial Supervisory Authority's website ([www.fi.se](http://www.fi.se)). Subscription forms will be available on the Company's, Nordic Issuing AB's, and Redeye AB's respective websites.

## Timetable for the Rights Issue

March 4, 2022	Record day in the Rights Issue
March 9 – March 18, 2022	Trade in subscription rights
March 9 – March 23, 2021	Subscription period
March 9, 2022 – until the Rights Issue is registered	Trading in paid subscribed shares (Sw. betalda tecknade aktier, "BTA")

with the Swedish Companies Registration Office	
March 28, 2022	Estimated date for publication of the outcome of the Rights Issue

### Advisers

Redeye AB acts as financial advisor, Advokatfirman Lindahl KB acts as legal advisor and Nordic Issuing AB acts as an issuing agent in connection with the Rights Issue.

### For further information, please contact:

Anna Eriksrud, CEO

Phone: +46 708 444 966

E-mail: [anna.eriksrud@neodynamics.com](mailto:anna.eriksrud@neodynamics.com)

### About NeoDynamics

NeoDynamics AB (publ) is a Swedish medical technology company that works to improve the diagnosis and treatment of cancer. The company's first product NeoNavia®, which is a new pulse biopsy system for ultrasound-guided tissue sampling, is now being introduced to the market. The biopsy system is based on a patented pulse technology based on research at Karolinska Institutet in Sweden. NeoNavia® is being evaluated for the diagnosis of breast cancer at leading clinics in the UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in the breasts and lymph nodes of over 500 patients.

### About NeoNavia

NeoNavia is a modern biopsy system with a completely new patented pulse technology that is intended to be used for ultrasound-guided tissue sampling. It consists of a base unit, a handset and three types of biopsy needles. Each needle type is driven by the new pulse technology that provides a more controlled needle insertion and precise placement of the needle in the tumor while enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer doctors and patients a precise and reliable tissue sampling that enables a correct diagnosis and individualized treatment.

### IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares or other securities in NeoDynamics. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden.

This release is not a prospectus in accordance to the definition in the Prospectus Regulation (EU) 2017/1129 ("**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares or other securities in NeoDynamics. A prospectus has been prepared and in connection with the Rights Issue and has been reviewed and approved by the Swedish Financial Supervisory Authority (Sw. *Finansinspektionen*) which is the national competent authority in Sweden with regard to the Prospectus Regulation. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the Prospectus. Thus, investors are encouraged to review the Prospectus in its entirety. In accordance with article 2 (k) of the Prospectus Regulation this press release constitutes an advertisement.

The information in this press release may not be released, distributed or published, directly or indirectly, in or into the United States of America, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction in which such action would be unlawful or would require registration or any other measures than those required by Swedish law. Actions in violation of these

restrictions may constitute a violation of applicable securities laws. No shares or other securities in NeoDynamics have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933, as amended (the “**Securities Act**”) or the securities legislation of any state or other jurisdiction in the United States of America and no shares or other securities may be offered, sold or otherwise transferred, directly or indirectly, in or into the United States of America, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States of America.

Within the European Economic Area (“**EEA**”), no public offering of shares or other securities (“**Securities**”) is made in other countries than Sweden. In other member states of the EU, such an offering of Securities may only be made in accordance with the Prospectus Regulation. In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under national law.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “**Order**”); (ii) high net worth entities etc. falling within Article 49(2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release may contain forward-looking statements which reflect the Company’s current view on future events and financial and operational development. Words such as “*intend*”, “*expect*”, “*anticipate*”, “*may*”, “*believe*”, “*plan*”, “*estimate*” and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.